Cutaneous epithelial tumors induced by vemurafenib involve the MAPK and Pi3KCA pathways but not HPV nor HPyV viral infection (Q35381501)

8 August 2017

title

Cutaneous epithelial tumors induced by vemurafenib involve the MAPK and Pi3KCA pathways but not HPV nor HPyV viral infection (English)

1 reference

8 August 2017

Jérome Solassol

9

0 references

author name string

Eric Frouin

1

1 reference

8 August 2017

Bernard Guillot

2

1 reference

8 August 2017

Marion Larrieux

3

1 reference

8 August 2017

Ariane Tempier

4

1 reference

8 August 2017

Nathalie Boulle

5

1 reference

8 August 2017

Vincent Foulongne

6

1 reference

8 August 2017

Céline Girard

7

1 reference

8 August 2017

Valérie Costes

8

1 reference

8 August 2017

language of work or name

English

0 references

publication date

31 October 2014

1 reference

8 August 2017

1 reference

8 August 2017

volume

9

1 reference

8 August 2017

issue

10

1 reference

8 August 2017

page(s)

e110478

1 reference

Creative Commons Attribution 4.0 International

8 August 2017

copyright license

start time

31 October 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

No human virus sequences detected by next-generation sequencing in benign verrucous skin tumors occurring in BRAF-inhibitor-treated patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

RASopathic skin eruptions during vemurafenib therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

Squamoproliferative lesions arising in the setting of BRAF inhibition.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

Association between H-RAS T81C genetic polymorphism and gastrointestinal cancer risk: a population based case-control study in China

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

Mutations of the BRAF gene in human cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

Persistence of human papillomavirus DNA in benign and (pre)malignant skin lesions from renal transplant recipients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

Improved amplification of genital human papillomaviruses

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

A broad range of human papillomavirus types detected with a general PCR method suitable for analysis of cutaneous tumours and normal skin

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients

12 July 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0110478

Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0110478

Vemurafenib (PLX-4032)-induced keratoses: verrucous but not verrucae

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0110478

HRAS T81C polymorphism modulates risk of urinary bladder cancer and predicts advanced tumors in ethnic Kashmiri population

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0110478

H-RAS 81 polymorphism is significantly associated with aneuploidy in follicular tumors of the thyroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0110478

Influence of single nucleotide polymorphisms in H-Ras and cyclin D1 genes on oral cancer susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0110478

Merkel cell polyomavirus DNA detection in lesional and nonlesional skin from patients with Merkel cell carcinoma or other skin diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0110478

Human polyomaviruses 6 and 7 are not detectable in Merkel cell polyomavirus-negative Merkel cell carcinoma

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

A single nucleotide polymorphism in the human H-ras proto-oncogene determines the risk of urinary bladder cancer.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215900

10.1371/JOURNAL.PONE.0110478

26 September 2018

Identifiers

DOI

1 reference

8 August 2017

0 references

1 reference

8 August 2017

1 reference